Following these proceedings, H.C. Wainwright initiated its Predictive Oncology Inc [POAI] rating to a Buy in a research note published on August 19, 2024; the price target was $3.
Price Performance Review of POAI
On Tuesday, Predictive Oncology Inc [NASDAQ:POAI] saw its stock fall -10.58% to $1.69. Over the last five days, the stock has gained 88.05%. Predictive Oncology Inc shares have risen nearly 106.10% since the year began. Nevertheless, the stocks have fallen -45.66% over the past one year. While a 52-week high of $3.76 was reached on 01/06/25, a 52-week low of $0.55 was recorded on 01/02/25. SMA at 50 days reached $0.8179, while 200 days put it at $1.1254.
Levels Of Support And Resistance For POAI Stock
The 24-hour chart illustrates a support level at 1.4633, which if violated will result in even more drops to 1.2367. On the upside, there is a resistance level at 2.0833. A further resistance level may holdings at 2.4767. The Relative Strength Index (RSI) on the 14-day chart is 74.04, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.6247, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 57.08%. Stochastics %K at 52.08% indicates the stock is a holding.
How much short interest is there in Predictive Oncology Inc?
A steep rise in short interest was recorded in Predictive Oncology Inc stocks on 2024-10-31, growing by 46045.0 shares to a total of 0.15 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.1 million shares. There was a rise of 30.91%, which implies that there is a positive sentiment for the stock.
